YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic ...
Recce Pharmaceuticals is up ~9% today after reporting positive patient data analysis from its phase II clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback